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Abstract: People who use drugs (PWUD) experience many social and health harms and are consid-
ered at greater risk of acquiring COVID-19. Little research has examined the impact of coronaviruses
either on PWUD, or on services targeted to PWUD. We report the findings of a systematic review of
empirical evidence from studies which have examined the impact of coronaviruses (Severe Acute
Respiratory Syndrome (SARS-CoV-1) and Middle Eastern Respiratory Syndrome (MERS-CoV) and
COVID-19) on PWUD or on service responses to them. Five databases were searched (MEDLINE,
PsycINFO, CINAHL, ASSIA and EMBASE) as well as COVID-19 specific databases. Inclusion criteria
were studies reporting any impact of SARS, MERS or COVID-19 or any service responses to those,
published between January 2000 and October 2020. Weight of Evidence judgements and quality
assessment were undertaken. In total, 27 primary studies were included and grouped by seven main
themes: treatment/recovery services; emergency medical settings; low-threshold services; prison
setting, PWUD/substance use disorder (SUD) diagnosis; people with SUD and HIV; ‘Sexual minority’
men. Overall, research in the area was scant, and of average/poor quality. More robust research is
required to inform on-going and future responses to coronavirus epidemics for PWUD.
Keywords: COVID-19; coronavirus; SARS; MERS; people who use drugs; problem drug users;
service responses; systematic review
1. Introduction
Globally, there are an estimated 35.6 million people experiencing ‘drug use disor-
ders’ [1] (defined as ‘intoxication by, dependence on, or regular, excessive consumption of
psychoactive substances’) [2]. Although the most common used drug globally is cannabis
and indeed drug markets are changing in terms of increased use of amphetamines and
of synthetic substances, those that are associated with most health-related harm are opi-
oids [1]. Approximately 58 million people use opioids and opioid users accounted for
66% of over 167,000 drug-related deaths (DRDs) in 2018 [1]. As well as DRDs, people
who use drugs (PWUD), experience multiple social and health harms, including blood
borne viruses (BBV) infections and are, in general, at elevated risk of premature mortality
compared to other groups [3]. DRDs have themselves been described as having reached
‘epidemic’ proportions in some countries including the United States of America (USA)
and Canada [4], and in Scotland (UK) as a public health emergency [5]. Within the UK,
Scotland has the highest rate of DRDs of any European country at 0.18 per 1000 (or 18 per
100,000) of the population [6]. In the USA and Canada, where prescription opioid use is
a major contributor to DRDs, the respective rates were 21.6 per 100,000 in 2020 [7] and
10.3 per 100,000 (opioid related deaths only) in 2019 [4].
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Factors that are known to contribute to DRDs vary between countries but include
increases in use of prescription opioids in North America [8] and poly-substance use,
concurrent benzodiazepine use and an ageing population of people with complex needs in
Scotland [6]. Additionally, however, structural factors such as poverty, stigma and economic
and social deprivation impact on the lives of PWUD and on the harms they experience
in regard to their health and wellbeing, including DRDs [9–11]. People who experience
problems with drug use also often have a higher prevalence of physical and mental health
issues than the general population [12,13]. Physical problems include cardiovascular
disease [14], respiratory illnesses [15], pulmonary disease, [16] asthma and diabetes, as
well as the impacts of BBVs [3]. Unfortunately, many of these illnesses are some of the
key ones which, if pre-existing in individuals, can make them more susceptible to having
poorer outcomes if they acquire COVID-19 [17,18].
COVID-19, a type of coronavirus, is a disease caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) [19]. It was first recorded in December 2019 and
has since become a global pandemic (declared by the World Health Organization on 11
March 2020) which already (at the time of writing) has infected over 120 million people
and led to more than 2.6 million deaths [20]). The countries with the highest rate of deaths
per 100,000 population from COVID-19 include the Czech Republic, the UK, Hungary, Italy
and the USA [20].
Prior coronavirus outbreaks that include both the Severe Acute Respiratory Syndrome
(SARS-CoV-1) in 2002 and Middle Eastern Respiratory Syndrome (MERS-CoV) in 2012
led to 1602 deaths in total [21]; the largest proportion of whom were males and between
41 and 60 years old [22]. Data that were published in the early stages of the COVID-19
pandemic showed that specific groups of people appeared to be at elevated risk of mortal-
ity from COVID-19, e.g., older people, males, those with specific underlying conditions
(cardiovascular, pulmonary, diabetes mellitus and asthma) [23] and those from poorer
neighbourhoods [24,25]. Ongoing research both on the prevalence and impact of COVID-
19 have continued to confirm these early data [26] as well highlighting the higher risk
of contracting the virus amongst people from black and minority ethnic (BAME) com-
munities. Sze et al. [27] provide systematic review level evidence that people who are
black and Asian are at higher risk of acquiring COVID-19 and that people from Asian
communities are at greater risk of mortality than their White counterparts [27]. Another
more recently identified feature of COVID-19 is that many people who have contracted
the virus continue to exhibit symptoms of the disease, sometimes very severe, for quite
some time afterwards. Researchers, and clinicians, are only beginning to understand the
phenomenon of post COVID syndrome (‘long COVID’), defined as ‘signs and symptoms
that develop during or following an infection consistent with COVID-19 which continue
for more than 12 weeks and are not explained by an alternative diagnosis’ [28]. It is not yet
known whether PWUD may be more or less likely than the general population to be at risk
of post-COVID syndrome. However, the similarities between the factors that appear to be
both predictors of, and have impacts on, people who contract COVID-19 and those that are
highly prevalent amongst PWUD are stark, suggesting that PWUD may be at greater risk
of mortality (and other harms) from COVID-19 than their non PWUD counterparts [29,30].
This review sought to establish the extent and quality of extant empirical evidence to
examine the impacts of SARS-Cov-1, SARS-Cov-2 (COVID-19) and MERS-Cov on PWUD
and on service responses to these coronavirus outbreaks of the 21st Century. The specific
aim and objectives are outlined below.
Aims and Objectives
The aim of this review is to inform current and future responses to coronavirus
outbreaks by identifying and critically appraising the empirical evidence relating to the
impact of novel coronavirus outbreaks of the 21st Century on problem drug users, with a
particular focus on COVID-19, on drug related deaths and other drug-related harms, as
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well as on service responses to problem drug use (PDU) including any evidence of the
effectiveness of such responses. The four review questions were:
1. What evidence exists regarding the impacts of any of the novel coronavirus outbreaks
of the 21st Century, including COVID-19, on PWUD, drug-related deaths and other
harms and what is the quality of evidence?
2. How have services who provide support for PDU and policy makers responded to
any of the 21st Century outbreaks, including COVID-19, and what is the quality of
evidence supporting their responses?
3. What are the gaps in evidence and what are the future research questions of impor-
tance in responding to any future outbreaks?
4. What are the implications of past responses to coronavirus epidemics/pandemics to
inform future service and policy responses?
2. Materials and Methods
The protocol for the systematic review was registered with PROSPERO, an international
prospective register of systematic reviews and can be accessed online [CRD42020211227].
In addition, the review was conducted in accordance with the Preferred Reporting for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines [31]. The completed PRISMA
checklist is included as Supplementary File S1.
2.1. Search Strategy
The following databases were searched: MEDLINE, PsycINFO, CINAHL, ASSIA,
and EMBASE.
The search strategy adopted the following search architecture:





6. 1 OR 2 OR 3 OR 4 OR 5
7. Problem Drug Users OR People who use drugs OR people who inject drugs
8. 6 AND 7
9. Limit 8 to English language; limit 8 to year range 2000–2020
We also conducted a further search which included the use of COVID-19 specific
search engines including CoViz, the ResearchGate COVID-19 search community, Lit Covid;
COVID-19 EPPI Centre living map of evidence and Evidence Collection from EvidenceAid
UK and OpenGrey. Electronic backwards and forwards citation searching of papers identi-
fied were also undertaken and we wrote to key authors in the field to ask if they were aware
of any recently completed or ongoing studies. The search results were deduplicated and
then citations screened according to the criteria detailed below. The full search architecture
is given in Supplementary File S2.
2.2. Inclusion and Exclusion Criteria
The included studies focused on problem drug users/people who use drugs or services
targeted to PWUD and included studies of any design and reporting any outcome. Full
details of the inclusion and exclusion criteria are given in Table 1 below.
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Table 1. Inclusion and Exclusion criteria.
Inclusion Exclusion
Studies reporting any impact on people who
use drugs (PWUD) due to Severe Acute
Respiratory Syndrome (SARS), Middle Eastern
Respiratory Syndrome (MERS) or COVID-19
Studies reporting any service response to
PWUD due to SARS, MERS or COVID-19
Qualitative, quantitative, mixed methods or
review papers
Non empirical studies, i.e., commentaries,
editorials, opinion pieces
Published in English Published in language other than English
Published between 2000 and October 2020 Studies published prior to 2000
2.3. Data Extraction and Reporting
All titles and abstracts from the initial list of potential studies were screened inde-
pendently by two members of the study team to identify studies to be included in full
text screening (AM and SM). Where there was disagreement between the researchers,
reports were retained for further examination. Selection was based on the above inclusion
and exclusion criteria. Two members of the study team independently examined full-text
copies of all selected papers for eligibility (AM and SM), and disagreements were resolved
by consulting with a third team member (JL). Data were then extracted from the studies
selected for inclusion. An Excel spreadsheet was used to record extracted information.
All included papers were scrutinised, and the following categories of data were
extracted by one reviewer (SM): study type; study aims; study methods; study setting;
country study took place in; year study took place; study population; main study findings;
study conclusions. Data were tabulated according to these categories and then sorted to
facilitate descriptive reporting.
2.4. Study Assessment/Quality Assessment
We adopted the Evidence for Policy and Practice Information and Co-ordinating
Centre [32] approach to assessing quality and relevance of studies: EPPI-Centre weight of
evidence (WoE) judgements were applied to each of the included studies. Three compo-
nents were assessed to help derive an overall weighting of evidence score: methodological
quality, methodological relevance and topic relevance. These components are detailed in
Table 2 below.
Table 2. Components of the EPPI-Centre weight of evidence score.
WoE 1 Components Definition Scoring Range
Methodological Quality
The trustworthiness of the
results judged by the quality
of the study within the
accepted norms for







The appropriateness of the







The appropriateness of focus







1 Weight of evidence.
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Assessment of overall weight of evidence (WoE) was made based on the assessments
for each of the above criteria and by using the same scoring system.
2.5. Additional Quality Assessment
We also conducted a more detailed assessment of the methodological quality of the
included studies based upon individual elements of study quality.
2.5.1. Qualitative Studies
All included qualitative studies were subject to an assessment of individual study
quality items, drawing upon Critical Appraisal Skills Program (CASP) [33] and COnsoli-
dated criteria for REporting Qualitative research (COREQ) criteria: triangulation of data,
rigor, reflexivity, credibility, relevance, and clear exposition of ethical issues [34]. We also
considered the nature of the evidence reported in the qualitative studies and assessed these
in terms of the ‘typologies’ of their findings as described by Sandelowski and Barroso
(2003) [35]. These authors suggest that findings of qualitative studies can be classified on a
continuum of data transformation, from findings that are not qualitative (no finding, topical
survey), to ones that are exploratory (thematic survey), descriptive (conceptual/thematic
description) or explanatory (interpretive explanation).
2.5.2. Quantitative Studies
All included questionnaire surveys were subject to an assessment of individual study
quality items. Key items of methodological quality of questionnaire surveys assessed
were representativeness of the sample (to the population from which they were drawn);
validated questionnaire (was a previously validated questionnaire used); response rate;
whether or not the study was longitudinal as opposed to cross-sectional; missing data;
generalisability of study findings.
2.5.3. Service Evaluation Studies
Those studies that employed a method of service evaluation or an approach to
analysing service use via existing data such as electronic health records were assessed
against the following four criteria: representativeness of sample studied, prospective
rather than retrospective, longitudinal rather than cross-sectional and generalisability of
study findings.
3. Results
The results of searching multiple sources for literature reporting empirical studies
resulted in 2759 publications being screened (see Figure 1 below). Screening by title and
abstract resulted in 2632 being excluded due to not fitting inclusion criteria. In total,
127 publications were retained and retrieved in full for further detailed scrutiny. Subse-
quently, 98 further studies were excluded because they were not reports of an empirical
study and/or they did not focus on PWUD. Twenty-seven reports of empirical studies
were located.
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ducted in North America (14) and the remaining 13 were conducted in Spain (2) and 1 
each in Australia, Finland, India, Italy, Netherlands, Nigeria, Norway, Poland, UK and 
Ukraine, with the final study involving participants from multiple countries. Twenty-five 
studies were quantitative and two were qualitative. No studies related to SARS-CoV-1 or 
MERS. Our analysis of studies indicated that they were best categorised with regard to 
their focus on treatment setting/services. Seven treatment settings were identified:  
 Treatment services/treatment/recovery (8 studies); 
 Emergency medical services (5 studies); 
 Low threshold services/shelter/homelessness (3 studies); 
 People who use drugs/with diagnosis of SUD (7 studies); 
 People with SUD and HIV (2 studies); 
 Sexual minority CIS men (1 study); 
 Prison (1 study). 
Figure 1. Flow diagram of study selection.
3.1. Overview of Study Characteristics
Table 3 provides an overview of the 27 primary studies included in the review (ordered
by weight of evidence and setting relevance). The majority of studies were conducted
in North America (14) and the remaining 13 were conducted in Spain (2) and 1 each in
Australia, Finland, India, Italy, Netherla ds, Nigeria, Norway, Poland, UK and Ukraine,
with the final study involving participants from multiple countries. Twenty-five studies
were quantitative and two were qualitative. No studies related to SARS-CoV-1 or MERS.
Our analysis of studies indicated that they were best categorised with regard to their focus
on treatment setting/services. Seven treatment ettings wer identified:
• Treatment services/treatment/recovery (8 studies);
• Emergency medical services (5 studies);
• Low thr shold services/sh lter/homelessness (3 studies);
• People who use drugs/with diagnosis of SUD (7 studies);
• Pe ple with SUD and HIV (2 studie );
• Sex al minority CIS me (1 tudy);
• Prison (1 study).
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Table 3. Characteristics of included studies (ordered by weight of evidence and setting relevance).











Fifteen People with Substance
Use Disorder (SUD) (11 under
treatment and 4 in recovery)
Netherlands Treatment and recovery B 2 1 1 2
Pandit 2020 [37] 4 male patients with SUD India Community; addiction treatmentcentre, outpatient service C 3 3 2 3
Quantitative studies
Glober 2020 [38]





USA Emergency Medical Services (EMS)Indianapolis B 2 2 1 2
Welle-Strand 2020 [39] 226 PWUD over 18 years. Norway
User organisations near the open
drug scenes and at low-threshold
services
B 3 1 1 2
Slavova 2020 [40]
People brought to emergency
services because of
experiencing opioid overdose
USA Emergency services for people whohave an opioid overdose C 2 2 1 2
Mariotinni 2020 [41]
All deaths occurring in




Finland Toxicology reports C 2 1 1 2
Martinotti 2020 [42]




Disorder (DSM-5) currently in
treatment as outpatients and/or in
a residency program as inpatients
recruited across Italy. Under
lockdown
C 3 2 1 2
Hochstatter 2020 [43]
64 People Living with HIV
(PLWH) and Substance Use
Disorders (SUD) (48 males, 15
females)
USA
Substance use and HIV
care—Opioid Relapse Prevention
and HIV Management
C 3 2 1 2
Ochalek 2020 [44]
Those presenting to emergency
department with nonfatal
unintentional overdose
USA Emergency department C 3 3 1 2
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Table 3. Cont.

















record (EHR) from 360 hospitals
and 317,000 providers across 50
states in the US since 1999
C 2 3 2 2
Starks 2020 [47]
455 CiS male 18 years+ who




USA Cis male LGBTQ+ community C 2 2 3 2
Whitfield 2020 [48]
People attending the 105 (91%)




UK NSP across Cheshire andMerseyside A 3 3 1 3
Bandara 2020 [49]
Wardens, sheriffs, medical
directors and other leadership
from 19 prisons
USA Prison C 3 2 1 3
Hawke 2020 [50]
622 youths aged 14 to
28 recruited across 4 existing
participant cohorts
Canada Based at Centre for Addiction andMental Health, Toronto B 3 2 3 3
Peacock 2020 [51]
People aged 18 or older who
have used ecstasy and other
illicit stimulants
Australia Adults who have used ecstasy andother illicit stimulants B 3 3 3 3
Seyed 2020 [52]
Unclear—aimed at substance
use treatment and harm
reduction services
Global Substance use treatment and harmreduction services B 3 3 2 3
Figgatt 2020 [53] 104 persons receivingmethadone from three clinics USA
PWUD receiving from
3 methadone clinics C 3 3 1 3
Trujols 2020 [54]
Take home medication
schedule (weeks) pre and post
COVID-19 for 102 patients
Spain Methadone Clinic Barcelona C 3 3 2 3
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Table 3. Cont.










Opiate, opioid, heroin, and/or
fentanyl related overdose
admission to emergency room






USA Prescriptions for Medications forOpioid Use Disorder C 3 2 2 3
Mellis 2021 [57] 1148 PWUD and family USA Members of the AddictionsPolicy Forum C 3 4 2 3
Rozanova 2020 [58]
123 older people with HIV




telephone interviews with HIV
and addiction service providers
Ukraine Older people with HIV receivingtreatment for HIV C 3 2 3 3
Wainwright 2020 [59]
75K + 75K (before and after
COVID-19) Individuals (urine
test results) with or at risk
of SUD
USA Nationwide lab urine results C 2 3 4 3
Nelson 2020 [60] 6 community drop in centresfor PWUD Nigeria
Community drop in centres for
PWUD in Nigeria C 4 3 1 4
Malczewski 2020 [61]





Poland Drug treatment services in Poland C 4 3 3 4
Program Evaluation
Martin 2020 [62] 27 homeless people residing ina municipal shelter Spain
Homeless people in Salamanca city
under lockdown in a
municipal shelter
C 3 3 2 3
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3.2. Quality Assessment
3.2.1. Weight of Evidence: Methodological Quality, Methodological Relevance and
Topic Relevance
As can be seen from Table 4, below, the methodological quality of included studies
was assessed mainly as less than ‘good’. No studies were rated as excellent in terms
of methodological quality, only 8 as good and 2 were rated as inadequate. In terms of
methodological relevance, ratings were better, with 4 rated as excellent, 9 as good, 13 as
satisfactory and 1 as inadequate. In total, 21 of the 27 papers were rated as good or above
in terms of topic relevance. However, with regard to overall weight of evidence, the studies
as a whole did not rate highly, with only 11 being rated as ‘good’ and the rest as either
satisfactory or inadequate. None were rated as excellent.
Table 4. Weight of evidence scores.
Components Excellent Good Satisfactory Inadequate
Methodological Quality 0 8 17 2
Methodological Relevance 4 9 13 1
Topic Relevance 12 9 5 1
Overall WoE 1 0 11 14 2
1 Weight of evidence.
3.2.2. The Additional Quality Assessment
The two qualitative studies were assessed as being credible and relevant but were
weaker on the other areas of quality assessed, such as rigor and reflexivity. Of the 13 studies
employing a survey method, only two reported a response rate of over 60%, and no studies
were rated as good for all elements of methodological quality. Of the 12 studies using other
quantitative observational methods, only two were longitudinal and none were prospective
suggesting limitations in terms of methodological robustness (please see Supplementary
File S3 for a summary of quality assessment).
3.3. Results Presented by Theme/Setting
As mentioned above, included studies were grouped by treatment/setting for analysis
and assessment of quality. The seven key settings are presented and discussed below.
3.3.1. Treatment/Recovery Services (Eight Studies)
The largest group of studies focused on treatment/recovery services (Table 5). Six
of the eight studies sought the views of PWUD regarding the impact of the COVID-19
pandemic [36,37,42,53,54,61]. There is good quality evidence that the pandemic has had
serious impacts on thoughts, feelings and behaviours such as stress, anger and feelings of
isolation. There is varied evidence (of mixed methodological quality) that the pandemic
has reduced quality of life amongst PWUD. In addition, one included UK study provides
‘satisfactory’ evidence that the impact of COVID-19 on PWUD was a reduction in Needle
and Syringe Program (NSP) clients as well as visits to NSPs during the initial stages of
the pandemic [48]. The impact was found to be greatest for those injecting image and
performance enhancing drugs.
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Table 5. Treatment services/treatment/recovery.










Recovery (4); 11 men









COVID-19 has had a serious impact on thoughts,
feelings, and behaviours. Thoughts were associated
with a range of negative feelings and behaviours, such
as stress, anger, avoidance, and isolation. Those still in
treatment were fighting against the temptation to start
using again; they felt emotionally isolated and










Challenges for patients with opioid use disorders in this
period, including increased risk of criminal charges due
to increased policing, fear of contracting COVID-19 and
transmitting it to family members, and stress due to
occupational disruption and financial difficulties.
Future policies should consider ways to enhance
capability to provide medication-assisted treatment
more easily to patients who have constrained resources,








diagnosis of SUD in
treatment; mean age






The presence of a moderate psychopathological burden
correlated to poor quality of life and low craving scores.
More than half of the cohort reported reduced quality
of life during COVID-19 lockdown, and the analysis
showed a negative correlation between perceived








clinics; aged 18 years
and over; 56% of the
sample were male; 90%






Before COVID-19, the clinic-level percent of
participants receiving any amount of days’ supply of
take-home doses at each clinic ranged from 56% to 82%,
while it ranged from 78% to 100% since COVID-19. The
clinic-level percent of participants receiving a
take-homes days’ supply of a week or longer
(i.e., ≥6 days) since COVID-19 ranged from 11% to 56%.
Among 87 participants who received take-homes since















Respondents from over 88% of countries reported that
core medical and psychiatric care for SUDs had
continued; however, only 56% of countries reported
having had any business continuity plan, and 37.5% of
countries reported shortages of methadone or
buprenorphine supplies. Participants of 41% of
countries reported partial discontinuation of
harm-reduction services such as needle and syringe
programs and condom distribution. In total, 57% of
overdose prevention interventions and 81% of outreach














The coronavirus epidemic has considerably affected the
Polish drug services, especially in terms of ensuring the
continuity of services at the adequate level. The
operation of inpatient clinics (residentials treatment)
and drop-in centres (harm reduction daily centre) has
been limited the most. It is worth noting that
substitution treatment has seen a higher demand for its
services, which was the consequence of opioid users
being deprived of income as a result of the epidemic.
The lack of financial resources made drug users decide
to enter opioid substitution treatment.
(WoE: 4 Inadequate)
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Table 5. Cont.







People attending the 105







COVID-19 related restrictions resulted in the number of
NSP clients decreasing by 36%, visits by 36%, and
needles distributed by 29%. NSP coverage for those
injecting psychoactive drugs halved, declining from
14 needles per-week during the 4 weeks to 15 March
2020 to 7 needles per-week by mid-April, and coverage












Take home medication (number of days provided)
overall increased significantly [t(101) = −7.759,
p < 0.001, d = 0.7680] comparing preCOVID-19
(6–12 March) vs. postCOVID-19 (13 March–12 May).
This increase did not lead to any detectable signs that
patients might be misusing/diverting medication.
(WoE: 3 Satisfactory)
3.3.2. Emergency Medical Services (EMS) (Five Studies)
All five of the studies that were set in EMS (Table 6) employed a quantitative
method [38,40,44,45,55]. All were pre- and post-studies of PWUD sampled from those
who had visited emergency departments or had contact with ambulance services before
and after stay-at-home restriction orders, and all were conducted within the USA. Four
of these studies ranked as ‘good’ with regard to overall weight of evidence and one was
satisfactory; though only three were also rated as ‘good’ in terms of methods. As a group
of studies these can be said to constitute the ‘strongest’ evidence in the included papers.
Table 6. Emergency medical services.
Study Method Participants Setting Main Findings
Glober
2020 [38]




office pre and post stay
at home order
2 Good
Calls to emergency medical
services with suspected
overdose or where naloxone was
administered or death by
overdose (actual number not
reported); participants were
predominately white (67 and
71% pre and post); 26 and 30%
black (pre and post); the
remainder described as ‘other’.
The majority of participants






Data regarding emergency medicine calls
for service (CFS) and suspected
accidental drug overdose deaths were
analysed. Overdose CFS and EMS
naloxone administration showed an
increase with the social isolation of the
Indiana stay-at-home order, but a
continued increase after the stay-at-home
order was terminated. Despite a mild 4%
increase in all EMS CFS, overdose CFS
increased 43% and CFS with naloxone
administration increased 61% after the
stay-at-home order. Deaths from drug











329 records of nonfatal,
unintentional opioid-related
opioid overdoses; the mean ages
were 42.2 years and 44.0 years,
71 (70%) and 165 (73%) were





Number of unintentional opioid-related
opioid overdoses increased (n =102
March–June 2019; n = 227 March June
2020). In March through June 2019 and
March through June 2020, 55 (54%) and
127 (56%) patients received a naloxone
prescription and 45 (44%) and 154 (68%)
received treatment resources and/or a
referral at discharge, respectively.
However, only 4 (4%) and 14 (6%) of the
17 (17%) and 46 (20%) admitted patients
received an addiction medicine consult,
and 3 (3%) and 23 (10%) accessed
treatment at the outpatient clinic after
overdosing, respectively.
(WoE: 2 Good)
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Table 6. Cont.












(C) USA (San Francisco)
Emergency departments saw
approximately 2.5 patients per day with
opioid overdose, compared with
1.4 patients per day prior to this period.
From 16 March to 18 April, there were
1.47 deaths per day, compared with
0.95 deaths per day prior to this period.
During the first weeks of a COVID-19
pandemic, emergency room
presentations and deaths related to






runs resulting in visits
to Emergency Room
before and after onset of
COVID-19 pandemic
2 Good
Emergency response records of
patients involved in ambulance





EMS runs in response to opioid
overdoses have significantly increased
since the COVID-19 crisis began. By
comparing the period before the
emergency declaration was made to the
period after the declaration, EMS runs
for opioid overdose have increased both
in the rate of transportation to ED and,
critically, in the number of those who














All 9-1-1 ambulance calls from
February 15, 2020 to 15 May
2020; mean age 51.6 years (pre
COVID-19) and 52.6 years post
COVID-19); males were 49.8% of
the pre sample and males and




Calls for substance-related reasons
decreased by 16.4% compared with prior
to the state-wide emergency. However,
despite an initial decrease in calls, after
the stay-at-home advisory calls for
substance use began increasing by 0.7
(95% confidence interval (CI) 0.4–1.1)
calls/day, while calls for other reasons
did not significantly change (þ1.2 (95%
CI −0.8 to 3.1) calls/day). Refusal of
transport for substance-related calls
increased from 5.0% before the
state-wide emergency to 7.5% after the
declaration (p < 0.001).
(WoE: 2 Good)
Three of the five studies suggested that opioid overdoses increased during the COVID-
19 stay-at-home order along with increased number of visits to the emergency department
for naloxone administration [38,44,55]. Similarly, two studies showed that emergency
medicine calls for opioid overdose increased during this time [40,45]. Two studies reported
an increase in drug overdose deaths [38,54] but only one of these was rated as ‘good’ in
terms of methods used and in weight of evidence.
3.3.3. Low Threshold Services/Shelter/Homeless (Three Studies)
Two of these three studies employed a quantitative method (Table 7) [39,60]. These
were questionnaire surveys of PWUD sampled from homeless populations and those who
attended drop-in services. The remaining study was a program evaluation involving
structured interviews with homeless people, 33% of whom had a substance use disorder
(SUD) [62].
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Table 7. Low threshold services/shelter/homeless.






29 homeless people (a
proportion of whom had
substance misuse disorder
or psychiatric disorder);
27 evaluated; 67% male;
‘average’ age 37 years; 33%
had a SUD.
Hostel for confined
homeless of the city
council social services
(C) Spain (Salamanca)
Due to the pandemic caused by COVID-19,
social and healthcare circumstances relative
to homeless population, which usually are
complicated, could be even more difficult.
However, due to the intervention and
implementation of this new program in the
City Hall resources made by the Psychiatry
Service, the objectives of detecting, treating
and referring patients to social and mental
health care resources, turned the
unfortunate situation of the pandemic into









centres (n not reported).




(C) Nigeria (4 regions)
The lockdown limited the range and
quality of services provided, and
constrained uptake by PWUD. Service
utilisation declined from 375 users in
October 2019 to 198 in April, before
reaching 321 in May. Female users were
more affected by the disruption than men.
Cannabis was the drug most commonly
used by service users followed by opioids
and alcohol. There were significant gaps in
service provision, including limited
face-to-face counselling and









mean age 43.1, 73% males.
Isolation units for
COVID-19 positive PWUD
(B) Norway (3 cities)
The main finding was that current or recent
OMT experience (i.e., treatment
engagement) was associated with
improved knowledge of common
COVID-19 symptoms and about available
services. OMT may play an important role
in COVID-19 prevention, as current and
previous OMT patients were more likely to
be aware of COVID-19 symptoms, as well
as COVID-19 services available for PWUD.
(WoE: 2 Good)
Only one of these three studies was judged as ‘good’ overall (WoE), one was ‘satisfac-
tory’ and one was ‘inadequate’ indicating that the evidence around this group/setting is
not good overall from included papers. However, the paper that was judged as inadequate
in terms of overall WoE was one of the few to include analysis of the use of services
throughout the early stages of the pandemic by gender and concluded that service use by
women declined more than did service use by men (no analyses conducted using inferential
statistics) [60].
The program evaluation suggested that homeless people with a substance misuse dis-
order may experience greater difficulty accessing a range of health services and treatments.
One questionnaire survey indicated that those who were enrolled on Opioid Mainte-
nance Treatment (OMT) during the pandemic had greater awareness of the symptoms of
COVID-19 as well as access to services that they could attend highlighting the potential
importance of OMT programs for COVID-19 prevention [39].
3.3.4. People Who Use Drugs/with Diagnosis of Substance Use Disorder in Predominantly
Community Settings
All seven studies used quantitative methods: three were questionnaire based sur-
veys [50,51,57]; one was an assessment of urine samples pre and post COVID-19 [59]; one
was a large case–control study of electronic health records [46]; another also analysed
electronic health records [56], and the remaining one an analysis of post-mortem toxicology
data [41]. Table 8 shows that only two of these studies were judged as ‘good’ in terms of
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weight of evidence, and the remaining five were judged as satisfactory, meaning caution is
needed in interpreting the results.
Table 8. People who use drugs/with diagnosis of Substance Use Disorder in predominantly community settings.






14–28; 62% female; 61%
Caucasian
4 existing participant
cohorts based at the




Reports of pre-pandemic mental health
compared to intra-pandemic mental health
show a statistically significant deterioration
of mental health across clinical and
community samples (p < 0.001), with
greater deterioration in the community
sample. A total of 68.4% of youth in the
clinical sample and 39.9% in the
community sample met screening criteria
for an internalising disorder. Substance use
declined in both clinical and community
samples (p < 0.001), although 23.2% of
youth in the clinical sample and 3.0% in the
community sample met screening criteria
for a substance use disorder. Participants
across samples report substantial mental
health service disruptions (48.7% and







1,148 members of the APF
network of patients,
families and survivors;






via email to their national
(U.S.) network of patients,
families, and survivors
(C) USA (multiple states)
Individuals who reported a history of use
of multiple substances were more likely to
report that COVID-19 has affected their
treatment and service access and were
specifically more likely to report both use
of telehealth services and difficulties
accessing needed services. These findings
suggest that individuals with a history of
using multiple substances may be at
greater risk for poor outcomes due to







389 people aged 18 or
older who have used
ecstasy and other illicit
stimulants at least once
monthly in the preceding
six months
Median age 23; 65% males
Participants recruited
from the community via




(Preliminary results). Most participants
reported no change or a decrease in their
drug use since COVID-19 restrictions
compared to before March 2020, although
changes in use varied by drug. Perceptions
of drug availability were mostly that it
remained stable. Participants reported
negative impacts on mental health but did
not report difficulties engaging with
services for alcohol and drug-related
reasons and had sought information about
practices to reduce the risk of COVID-19




Cross sectional study of





of urine sent for testing;
aged 18 years and over;




who are diagnosed with or
at risk of substance misuse
(C) USA (multiple states)
This study demonstrated that urine drug
test positivity in a population diagnosed
with or at risk of substance use disorders
increased significantly for illicit cocaine,
fentanyl, heroin, and methamphetamine
from the 4 months before the COVID-19
emergency declaration to the 4 months
after the COVID-19 declaration.
(WoE: 3 Satisfactory)
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Table 8. Cont.








of whom 12,030 had a
diagnosis of COVID-19.
722,370 had been recently
diagnosed with SUD;
includes all age ranges;
predominantly Caucasians
Electronic health records
from 360 hospitals and
317,000 providers across
50 states in the US
since 1999
(C) USA (50 states
Patients with a recent diagnosis of SUD
(within past year) were at significantly
increased risk for COVID-19 (adjusted
odds ratio or AOR = 8.699 [8.411–8.997],
P < 10−30). Compared to patients without
SUD, patients with SUD had significantly
higher prevalence of chronic kidney, liver,
lung diseases, cardiovascular diseases, type
2 diabetes, obesity and cancer. Findings
identify individuals with SUD, especially
individuals with OUD and African
Americans, as having increased risk for
COVID-19 and its adverse outcomes,
highlighting the need to screen and treat
individuals with SUD as part of the
strategy to control the pandemic while










Data are pooled from
16 healthcare
organisations that span
11 states and cover
11.1 million patients
Receipt of prescription of
medications for opioid
use disorder
(C) USA (12 states)
The number of patients receiving first-time
prescriptions for Medications for Opioid
Use Disorder (MOUD) decreased by over
30% in the spring of 2020 when compared
to trends observed in EHR data from
January 2017 to May 2020. This finding
suggests that patients at risk for opioid use
disorder (OUD) and overdose are

















Immediately after government restrictions
in March 2020, the numbers of
buprenorphine, amphetamine and
cannabis findings increased. The increase
was most noticeable for amphetamine and
was evident in all age groups. Findings
indicate by association that there is an
increased risk of drug-related harm
(including death) in Finland.
(WoE: 2 Good)
The study by Wang and colleagues, conducted on data collected across the USA,
provides good evidence that people with a diagnosed SUD, and those categorised as
African American are at higher risk of contracting COVID-19 as well as adverse outcomes
from the virus [46].
Three of the remaining six studies, all surveys, suggested that substance use either
declined or did not change since the onset of COVID-19 restrictions [50,51,57]. Two of
the three surveys report a deterioration in mental health amongst both community and
clinical samples [50,51]; one reported reduced access to treatment services [57] and one
reported no issues for PWUD in terms of accessing services [51]. However, in contrast,
the cross-sectional study (judged ‘good’ in methods used) indicated increased use of the
illicit drugs, cocaine, fentanyl, heroin and methamphetamine amongst community samples
using data from multiple states [59].
The study by Little and colleagues [56] analysed prescription data of first-time pre-
scriptions for Medications for Opioid Use Disorder (MOUD) and found that these had
decreased by over 30% in the spring of 2020 when compared to trends observed in electronic
health record data from January 2017 to May 2020.
The final study in this group reported a before and after ‘stay at home orders’ study
of post-mortem toxicology cases found to be positive for buprenorphine, amphetamine or
cannabis in the first 8 months of the year 2020 [41]. They found that for the period directly
after the government restrictions came into force in March 2020, the numbers of positive
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screening for buprenorphine, amphetamine and cannabis increased in post-mortem data.
The increase was most noticeable for amphetamine and was evident in all age groups.
3.3.5. People with HIV and Substance Use Disorder
Both of the studies of people with SUD and HIV were surveys; one was judged
as ‘good’ in terms of WoE and one as ‘satisfactory (Table 9)’. Both were judged only as
‘satisfactory’ in terms of methods. One study reported that people with SUD and HIV had
increased their illicit drug use and were less confident about staying sober/abstinent and
attending recovery services during the pandemic [43]. The other survey of older people
with SUD and HIV found that, whilst this group maintained SUD and HIV therapy during
the pandemic, social support was critical in avoiding treatment interruptions [58].
Table 9. People with HIV and Substance Use Disorder.




6 weeks before national
emergency compared to 6
weeks after
3 Satisfactory
60 individuals with SUD
and HIV; 75% male; 59%
black or African American,







During the pandemic, people who live
with HIV and SUD increased illicit
substance use and contact with other
substance-using individuals and
decreased their confidence to stay sober
and attend recovery meetings. The
proportion of people missing their HIV
medications also increased, and








123 older people (aged
>50) with HIV and SUD;
47% women,





treatment and care for
older people with HIV
and SUD
(C) Ukraine (Kyiv)
While older people with SUD
maintained HIV and SUD therapy
throughout COVID-19 lockdown, social
support is critical to avoiding treatment
interruption. COVID-19 lockdown may
disrupt MAT and ART among older
people with HIV and SUD not only while
being in place, but also during the
reopening. After recent increases of
support by clinicians, subsequent
reduction of support may lead to people
feeling even more isolated.
(WoE: 3 Satisfactory)
3.3.6. ‘Sexual Minority’ Men
Only one study of ‘sexual minority’ cisgender (Cisgender men refers to ‘non trans-
gender’ people [63]) men was included in the review (Table 10). This study employed a
matched control design using survey methods and found that while drug use declined
amongst this group after the pandemic started, sexual risk-taking behaviour did not [47].
Table 10. Sexual minority men.











455 adult sexual minority
CIS males who use drugs;
age range 18+; 47%
‘white’; 29% ‘black’; 14%
Latino; 10% other; drugs
mainly marijuana
Geosocial networking apps for
gay, bi, trans, and queer




an image of one or more
adolescent or adult males.
(C) USA (multiple states)
While the proportion of
participants reporting marijuana
and other illegal drug use as
well as CAS with casual partners
declined during COVID, the
association between other illegal
drug use and sexual risk
behaviour was amplified.
(WoE: 2 Good)
Int. J. Environ. Res. Public Health 2021, 18, 8470 18 of 26
3.3.7. Prison
This single study (Table 11) was a survey of prison staff across various prisons in the
USA and found that there were disruptions to medication dispensing processes including
medication-assisted treatment (MAT), i.e., Opioid Agonist Treatment (OAT), because of
challenges in maintaining social distancing and obtaining personal protective equipment
(PPE) at the time. This study was judged as ‘satisfactory’ in terms of both WoE and methods
used [49].
Table 11. Prison setting.









19 prisons (14 county jail






(C) USA (multiple states)
Ten out of 16 systems reported
downsizing their OAT programs. Seven
of 16 systems made changes to
medication dispensation processes. Half
of systems report challenges
implementing physical distancing (n 14 8),
and/or obtaining personal protective
equipment (n 14 8). In 13 out of 16 systems
some OAT program participants were




To the best of our knowledge, this is the first systematic review to report the results of
a review of empirical evidence only that was conducted specifically to assess the impact
of SARS-1, MERS and COVID-19 on problem drug users. From the 27 empirical papers
included, we found that they were best grouped and described under the seven themes
listed in the preceding Results Section. This section discusses the key study findings
including implications for the ongoing pandemic as well as future coronavirus pandemics.
Although the included studies are limited in number and in quality overall, several
discussion points emerge from the study results and cut across the study groupings. These
are impact on psychological and physical wellbeing for PWUD including for ‘vulnerable
groups’ (e.g., people who were homeless at the time of the pandemic, and BAME groups);
restricted access to services and service ‘innovations’ to mitigate some potential restrictions;
impacts on drug-related deaths and other harms; drug use patterns themselves.
4.1. Psychological and Physical Wellbeing
Several studies examined the impact of COVID-19 on psychological and physical
wellbeing of PWUD and found, perhaps unsurprisingly, that impacts were detrimental and
in different ways. While out of the scope of our review, it is clear from research conducted
on even general populations that the impact of COVID-19 including the experience of social
restrictions has led to increases in both anxiety and depression globally [64]. Additionally,
there is increasing evidence that the impact on mental health has been comparatively much
worse in other vulnerable groups (such as those in insecure housing, BAME groups, and
those with pre-existing mental health conditions, and those with low social support [65,66].
Given that PWUD can be defined themselves as a vulnerable population then it would
seem reasonable to suggest that additional supports for both physical and psychological
health may need to be put in place, prospectively, if further pandemics such as this occur.
4.2. Vulnerable Groups
Many jurisdictions including countries of the UK and Ireland, Spain and the USA
recognised early in the pandemic that people who were homeless would be additionally
vulnerable to COVID-19 as well as to drug-related harms if interventions were not in situ
place to house them. These studies were few and again of limited quality. However, they
highlighted that creating specific measures to support people who were homeless could
Int. J. Environ. Res. Public Health 2021, 18, 8470 19 of 26
be effective [62], that being in contact with harm reduction services was an effective way
to convey important knowledge and information about COVID-19 [39] and potentially
that women who use drugs were more affected by service disruptions than men [60]. In
Scotland and the UK, people who were homeless (significant proportions of whom tend to
be PWUD) were also provided with temporary accommodation in hotels during the initial
wave of the pandemic [67,68] but the outcomes and impacts of these initiatives are currently
under-researched (or under-reported) and so the results of these initiatives are not yet
known. However, one recent qualitative study in Scotland found that maintaining access
to services for PWUD who are homeless was a lifeline during the pandemic [69]. Another
subsequent case study, conducted in Dublin (Ireland), where health services specifically
expanded harm reduction services for people who were homeless during the pandemic,
resulted in improved access to MAT and Naloxone (opioid overdose reversal drug) and the
home delivery of key medications for PWUD (e.g., methadone and benzodiazepines). The
authors concluded that the pandemic provided a basis on which to successfully remove
regulatory obstacles and improved the political will to improve access to these lifesaving
interventions [30]. It is important that future research examines the outcomes of all these
measures and that in the event of another pandemic that the evidence base for these
additional measures is known.
Only one included study examined the risks of contracting COVID-19 amongst PWUD
and found that people with a recent diagnosis of SUD (within the past year) were at
increased risk of contracting COVID-19 compared to people without that diagnosis. This
study also found that people with opioid use disorder (OUD) and those who were African
American had increased odds of contracting COVID-19 and therefore are at higher risk for
adverse outcomes [46]. While no other included studies examined the odds of contracting
COVID-19 amongst people with SUD, there is a growing body of research that has shown
that PWUD may be at greater risk of acquiring COVID-19, due to less ability to socially
distance [70] and the increased risk of ‘non-White’ groups of contracting COVID-19 [71,72].
PWUD who are incarcerated are another important vulnerable group but only one
study conducted in a prison setting met our inclusion criteria [49] and found reductions
in the provision of OAT. Reducing access to ‘life saving’ medications such as OAT may
impact negatively on an already vulnerable population. There is already good evidence of
the effectiveness of OAT in prisons in preventing overdose, drug-related deaths [73] and
in reducing mortality and improving other post imprisonment outcomes [73,74] and so
maintenance of this access during a pandemic is particularly important.
4.3. Reduced Access to Treatment and Harm REDUCTION Services
Several studies reported reduced access to harm reduction services owing to the
pandemic [48,52,61] though only one study inferred that this was related to a subsequent
rise in DRDs [41]. More recent research has provided further evidence of the impacts
of reduced service access including reductions in uptake of injecting equipment and
MAT as well as a reduction of uptake of HIV and other BBV testing in Spain, UK and
Sweden [75–77]. However, one recent study conducted in Sweden [76], which unlike many
other countries did not impose a general societal lockdown, reported that harm reduction
services were accessed as usual (at worst) during the initial stages of the pandemic and
that distribution of needles and syringes increased. DRDs were found to have decreased
over the period of study. In addition, this study showed that prevalence of SARS-CoV-2
was low amongst PWUD compared to the general population. These are noteworthy
findings and suggest that although PWUD may have heightened risk factors for acquiring
COVID-19, specific governmental and service responses—such as keeping services open
(as best as possible)—may mitigate these risk factors. This is an important consideration
for other jurisdictions.
Other mitigation measures that were introduced during periods when social re-
strictions were in place were increasing dispensing of take-home medications such as
methadone. In the results section we noted that two of the included studies examined
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increases in the provision of take-home medication (OAT) during the initial stages of
the pandemic and found there to be few negative consequences associated with this in
terms of diversion of medication [52–54]. These are interesting findings as the issue of
non-supervised consumption of OAT is a contested topic and especially relating to concerns
over the diversion of medication and potential increased risk of overdose [78]. Research on
this issue conducted prior to the pandemic has found that safe storage of these medicines
at home can be problematic and can also pose a risk to others living in the household (e.g.,
children) [79], and that safety guidance is sometimes neither adequately presented nor
adequately recalled by PWUD potentially exacerbating problems with safe storage [79,80].
A recently published paper based on interview data with PWUD during the pandemic
found that the diversion of medication was used as a means of helping other PWUD to
avoid withdrawals as well as to provide other sources of finance when social restrictions
had educed opportunities for financing for PWUD [78]. Further research is required on
the efficacy of this approach, including outcomes, to enable planning for future service
provision including further lockdowns and pandemics.
4.4. Drug Related Deaths
Arguably the ‘strongest’ studies included in our review were those that we grouped
under ‘emergency medical settings’ [38,40,44,45,55]. All were conducted in the USA and
most used very large secondary data sets which suggested that both fatal and non-fatal
drug overdoses had increased in the early stages of the pandemic. Two studies that
examined ambulance call data showed that overall calls (or ambulance runs) relating to
drug overdoses increased after the pandemic began but also that there was an increase
in instances of refusals of transport for substance-related calls [40,45]. These studies raise
concerning issues that also require further research but if either of these key findings are
replicated elsewhere then the consequences for PWUD and the ongoing public health
emergency of drug-related deaths will continue to escalate. One large scale qualitative
study of the experiences of PWUD in Canada suggests that the risk of fatal and non-fatal
overdose may have been elevated in part because of PWUD being compelled to use drugs
other than their usual drug(s) of choice because of the disruptions to routes of drug supply
in the pandemic [81]. In essence, switching to different types of drug use can lead to
a reduction in drug tolerance and put people at greater risk of overdose [81]. Further
investigation of what might explain the causes of increases in drug overdoses, and how
best to mitigate them, during the pandemic is also required as a matter of urgency. While
the reasons for this were not greatly discussed in our included papers, one paper did
associate the increase in DRDs with reduced access to harm reduction services [41]. Given
the known effectiveness of MAT and naloxone in preventing DRD [3,82] then reductions
and/or new barriers to accessing these life-saving interventions could indeed feasibly lead
to increases in fatal drug overdose and it would seem apt to conclude that ensuring the
continuation of these critical services in future would be an important mitigation measure
during any future pandemic.
4.5. Drug Use Patterns
Only three of the studies included examined impacts on drug use per se and each
found a different result: one reported a decrease in drug use, one reported no change or a
decrease in drug use and one reported an increase, thus presenting an inconclusive picture
on the true impact [50,51,59]. None of our papers included research on novel psychoactive
substances but there is evidence some countries have seen increases in the use of these
drugs over the course the pandemic [83,84]. Nevertheless, this inconclusive evidence
relating to whether drug use has increased or decreased has subsequently been supported
in a trans-European study (seven countries) using wastewater analysis to examine the
impact of ‘stay at home orders’ measures on specific stimulant and cannabis use. This study
found that the picture was heterogenous rather than uniform indicating that potential
responses to changes in drug use patterns are therefore hard to predict [85].
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4.6. Answering the Research Questions
This review set out with four specific review questions. The answers to these are
the following:
4.6.1. Question 1. What Evidence Exists Regarding the Impacts of Any of the Novel
Coronavirus Outbreaks of the 21st Century on Problem Drug Users, including COVID-19,
Drug-Related Deaths and Other Harms; What Is the Quality of the Evidence?
The only empirical evidence available in relation to our question about problem drug
users relates to the COVID-19 pandemic and the quality of evidence is very limited, both in
terms of the types of methods employed (mostly observational and some limited qualitative
research) but also in terms of how well these methods were applied and reported. There is
also limited empirical evidence on the impact of COVID-19 on drug harms and little data
related specifically to drug deaths.
4.6.2. Question 2. How Have Services Who Provide Support for PDU and Policy Makers
Responded to Any of the 21st Century Outbreaks, including COVID-19 and What Is the
Quality of the Evidence Supporting Their Responses?
There is limited empirical evidence relating to the responses of services and policy
makers during the current pandemic and of the empirical data that do exist they mainly
concern evaluations of service usage. However, although no empirical research on the
impact of COVID-19 on services themselves met our inclusion criteria (i.e., was found at
the time searches for this review were conducted), some of the papers included here as part
of our discussion do refer to service reductions and some claim that reductions in service
provision have impacted negatively on issues such as initiation of people on methadone
for the first time and even have resulted in higher numbers of DRDs.
4.6.3. Question 3. What Are the Gaps in Evidence and What Are the Future Research
Questions of Importance in Responding to Any Future Outbreaks?
Our review shows that there are many gaps in evidence regarding the impacts on
PDU and service/policy responses. The gaps in research relate primarily to three key areas:
to the impact on individuals, to the extent and impact of service changes; policy responses.
Some of the key areas for research identified relate to the immediate and longer term
impacts of COVID-19 (both directly and indirectly) on PWUD, including less researched
or additionally vulnerable PWUD (e.g., women, BAME communities, people in recovery
communities); what are the impacts of new modes of service delivery that have occurred
since the pandemic and what are the unintended consequences of these; finally, what
impact have policy decisions had on PWUD and on service staff and service provision?
4.6.4. Question 4. What Are the Implications of Past Responses to Coronavirus
Epidemics/Pandemics to Inform Future Service and Policy Responses and Specifically
in Scotland?
No empirical studies were found relating to PWUD concerning past responses in
previous coronavirus epidemics/pandemics.
5. Strengths and Limitations
The strengths of this review are that we included only empirical evidence and so there-
fore we excluded commentary and opinion pieces. In addition, we used a systematic and
robust approach that details stages of the process and includes rigorous quality assessment.
We also searched multiple sources to accommodate and account for the emergent nature of
the pandemic and we published a prior protocol.
A limitation of the study relates in part to the limited range and quality of the included
studies which in turn impact on providing detailed answers to our research questions. A
second limitation is that we may have missed studies that were on-going, or unpublished at
the time. This is particularly the case during the COVID-19 pandemic when many research
funding bodies have specifically re-oriented (at least some) funding towards research on
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myriad aspects of the pandemic and hence increases the likelihood of there being on-going
studies that we were not able to include.
6. Conclusions
The full impact of the current COVID-19 pandemic is not yet known, nor is its impact
on people who use drugs and on the services which provide support and treatment to
people who use drugs. However, our review of relevant empirical studies conducted up
until the end of October 2020 highlights that few empirical studies have been conducted to
examine the impacts on or experiences of PWUD. No studies were found that addressed
these issues during the SARS-Cov-1 or MERS coronavirus epidemics.
The range of study types is narrow: most are observational and only few are qualita-
tive. Only two qualitative studies were located. Overall, the quality of included studies
was not high—most were judged as satisfactory or inadequate.
We conclude that the empirical evidence is generally not of sufficient quality to
inform future responses to further COVID-19 outbreaks or indeed other novel coronavirus
outbreaks but we have noted where consideration may be given to some interventions
such as maintaining access to evidenced based interventions (e.g., MAT and naloxone) as
well as a need for additional supports for more vulnerable PWUD such as people who are
homeless, who have additional comorbidities and from BAME groups. There remains a
large gap in knowledge that is necessary to inform future responses.
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